What is the latest selling price of Clofazimine in 2025?

Clofazimine (Clofazimine) is a drug with antibacterial and immunomodulatory effects. It was initially mainly used in the combined treatment of leprosy. Because it has an inhibitory effect on Mycobacterium leprae, it can help reduce the risk of recurrence, and it also shows a strong control effect in leprosy associated with inflammatory reactions or erythematous nodular leprosy. Therefore, it has been included as one of the basic medicines in clinical practice for a long time. In recent years, with the deepening of medical research, the application scope of clofazimine is gradually expanding, and some scholars are exploring its potential value in drug-resistant cases of Mycobacterium tuberculosis and other chronic infectious diseases. This has caused the drug to once again attract attention around the world.

In the domestic market, clofazimine has been routinely supplied and included in the scope of medical insurance reimbursement, reducing the treatment burden for patients. At present, the common domestic specifications are 50mg*10 tablets, and the market price is about 500 yuan. The specific price will vary depending on regional policies, hospital procurement channels, and medical insurance reimbursement ratios. If patients have long-term medication needs, they can usually effectively reduce financial pressure with the help of medical insurance reimbursement policies.

From the international market, the supply of generic clofazimine drugs is more abundant. Taking India and other major pharmaceutical exporting countries as an example, the common specifications of their generic versions are 100mg*100 tablets, and the overall price is only about 400 yuan, which has certain advantages compared with domestic prices. Since generic drugs and original drugs have the same active ingredients and dosages, and their therapeutic effects are roughly the same, purchasing generic drugs overseas has become a choice for some patients.

Combining the domestic and foreign market conditions, it can be seen that the accessibility of clofazimine is gradually improving, whether through the reimbursement mechanism within the medical insurance system or the supply of overseas generic drugs, which can reduce the financial burden of patients to a certain extent. For patients, how to find a balance between price and drug safety is the most critical consideration.

Reference materials:https://www.novartis.com/our-products/pipeline/clofazimine